

Thomas Horvatits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7507548/publications.pdf>

Version: 2024-02-01

50
papers

1,527
citations

304743

22
h-index

315739

38
g-index

57
all docs

57
docs citations

57
times ranked

1942
citing authors

#	ARTICLE	IF	CITATIONS
1	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 556-568.	7.3	148
2	Microplastics detected in cirrhotic liver tissue. <i>EBioMedicine</i> , 2022, 82, 104147.	6.1	124
3	Liver Injury and Failure in Critical Illness. <i>Hepatology</i> , 2019, 70, 2204-2215.	7.3	88
4	The Clinical Perspective on Hepatitis E. <i>Viruses</i> , 2019, 11, 617.	3.3	85
5	HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. <i>Journal of Hepatology</i> , 2018, 69, 36-42.	3.7	80
6	Hypoxic liver injury and cholestasis in critically ill patients. <i>Current Opinion in Critical Care</i> , 2013, 19, 128-132.	3.2	75
7	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.	5.8	74
8	Renal replacement therapy in critically ill liver cirrhotic patientsâ€™ outcome and clinical implications. <i>Liver International</i> , 2017, 37, 843-850.	3.9	55
9	Monocytes as Potential Mediators of Pathogenâ€nduced Tâ€Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). <i>Hepatology</i> , 2020, 72, 1310-1326.	7.3	50
10	Circulating bile acids predict outcome in critically ill patients. <i>Annals of Intensive Care</i> , 2017, 7, 48.	4.6	49
11	Serum bile acids as marker for acute decompensation and acuteâ€nâ€chronic liver failure in patients with nonâ€cholestatic cirrhosis. <i>Liver International</i> , 2017, 37, 224-231.	3.9	47
12	Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. <i>Intensive Care Medicine</i> , 2013, 39, 1227-1237.	8.2	46
13	Hepatitis E seroprevalence in the Americas: A systematic review and metaâ€analysis. <i>Liver International</i> , 2018, 38, 1951-1964.	3.9	44
14	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 544-549.	3.7	43
15	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014, 60, 1135-1142.	3.7	39
16	Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in miceâ€. <i>Hepatology</i> , 2018, 68, 634-651.	7.3	39
17	Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. <i>JHEP Reports</i> , 2019, 1, 90-98.	4.9	30
18	Gender-specific differences in energy metabolism during the initial phase of critical illness. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 707-711.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. <i>Journal of Hepatology</i> , 2014, 60, 1187-1193.	3.7	28
20	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. <i>Annals of Intensive Care</i> , 2016, 6, 61.	4.6	28
21	Acidâ€base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. <i>Annals of Intensive Care</i> , 2018, 8, 48.	4.6	24
22	Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. <i>Journal of Clinical Virology</i> , 2018, 105, 26-30.	3.1	23
23	Outcome of in- and out-of-hospital cardiac arrest survivors with liver cirrhosis. <i>Annals of Intensive Care</i> , 2017, 7, 103.	4.6	21
24	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. <i>International Journal of Obesity</i> , 2021, 45, 2197-2204.	3.4	21
25	Pharmacokinetics of Ganciclovir during Continuous Venovenous Hemodiafiltration in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 94-101.	3.2	20
26	Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation. <i>United European Gastroenterology Journal</i> , 2018, 6, 104-111.	3.8	19
27	Hypoxic liver injury after in- and out-of-hospital cardiac arrest: Risk factors and neurological outcome. <i>Resuscitation</i> , 2019, 137, 175-182.	3.0	19
28	Hepatitis E virus persists in the ejaculate of chronically infected men. <i>Journal of Hepatology</i> , 2021, 75, 55-63.	3.7	17
29	Therapeutic options in pulmonary hepatic vascular diseases. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 31-42.	3.1	16
30	Comparison of the integrin $\alpha 4 \beta 7$ expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. <i>PLoS ONE</i> , 2019, 14, e0220008.	2.5	16
31	Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and metaâ€analysis. <i>Liver International</i> , 2021, 41, 449-455.	3.9	16
32	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. <i>Annals of Intensive Care</i> , 2015, 5, 47.	4.6	14
33	No link between male infertility and HEV genotype 3 infection. <i>Gut</i> , 2020, 69, 1150-1151.	12.1	12
34	Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A. <i>Pathogens</i> , 2021, 10, 60.	2.8	11
35	Serum bile acids in patients with hepatopulmonary syndrome. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 361-367.	0.5	9
36	Extrahepatic manifestations and HEV, the genotype matters. <i>EBioMedicine</i> , 2018, 36, 3-4.	6.1	8

#	ARTICLE	IF	CITATIONS
37	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. <i>Pathogens</i> , 2020, 9, 755.	2.8	7
38	<scp>HEV</scp> in pregnancy: Understanding the crucial role of steroid hormones. <i>Liver International</i> , 2019, 39, 621-622.	3.9	5
39	Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. <i>Trials</i> , 2022, 23, 302.	1.6	5
40	Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival. <i>Annals of Hepatology</i> , 2021, 26, 100559.	1.5	4
41	Lack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General. <i>Pathogens</i> , 2022, 11, 18.	2.8	4
42	Lack of evidence for human serum albumin as major source of HEV infections. <i>Transfusion Medicine</i> , 2018, 28, 470-471.	1.1	2
43	SAT-208-Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy. <i>Journal of Hepatology</i> , 2019, 70, e721-e722.	3.7	2
44	Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 840-848.	1.5	2
45	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.9	1
46	Response for letter "Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries". <i>Liver International</i> , 2018, 38, 2341-2341.	3.9	1
47	HEV-Associated Neuralgic Amyotrophy: A Multicentric Case Series. <i>Pathogens</i> , 2021, 10, 672.	2.8	1
48	Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. <i>PLoS ONE</i> , 2021, 16, e0258450.	2.5	1
49	Hepatitis E. , 2021, , 329-335.		0
50	Hepatitis E, Schistosomiasis and Echinococcosis "Prevalence in a Cohort of Pregnant Migrants in Germany and Their Influence on Fetal Growth Restriction. <i>Pathogens</i> , 2022, 11, 58.	2.8	0